Abstract
TAZ, an enhancer of zeste homolog (EZH2) inhibitor, is approved for use in patients with epithelioid sarcoma or relapsed/refractory follicular lymphoma. Inhibition of EZH2 has been proposed to overcome resistance to the androgen signaling inhibitors (ASIs) A and E. In preclinical prostate cancer models, TAZ + E or TAZ + A/P led to greater tumor growth reduction than each drug alone. This phase Ib/II global, open-label, randomized study (NCT04179864) is evaluating the safety and efficacy of TAZ + A/P and TAZ + E in mCRPC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
